期刊文献+

沙利度胺联合放疗治疗食管癌长期生存分析 被引量:9

Long-term survival analysis of thalidomide combined with radiotherapy for patients with esophageal carcinoma
原文传递
导出
摘要 目的 研究沙利度胺下调食管癌患者放疗中血清血管内皮生长因子(vascular endothelial growth factor,VEGF)水平对食管癌患者长期生存的影响.方法 根据81例食管癌患者放疗中血清VEGF水平分为用药组(沙利度胺)32例和未用药组49例,通过随访观察分析其总生存率(OS)和无进展生存率(PFS),根据32例使用沙利度胺处理后的血清VEGF水平变化,又分降低组20例和升高组12例,分析其OS和PFS.对预后因素进行单因素和多因素分析.结果 用药组和未用药组的中位生存期及1、3年生存率分别为17.0个月、59.4%、31.5%和18.7个月、56.4%、28.6%;两组的OS和PFS分别比较,差异均无统计学意义.VEGF水平降低组和升高组的中位生存期及1、3年生存率分别为19.7个月、65.0%、42.1%和10.7个月、43.3%、8.3%;两组OS和PFS比较,差异均有统计学意义(x2=4.345、4.157,P <0.05).多因素分析显示,临床分期是食管癌患者总生存率的独立预后因素,性别、病变部位对患者预后没有影响.结论 对于用药后VEGF水平降低患者,沙利度胺联合放疗能够增加食管癌患者远期疗效. Objective To study effect of thalidomide on the long-term survival outcome of esophageal carcinoma with radiotherapy by reducing serum vascular endothelial growth factor (VEGF) levels.Methods A total of 81 inoperable esophageal cancer patients were divided into two groups according to serum VEGF levels during radiotherapy:treatment group (thalidomide) with 32 patiens and untreatment group with 49 patients.Overall survival (OS) and progression free survival (PFS) were analyzed for these two groups.Twenty patients whose VEGF level decreased after thalidomide were defined as decreased group,and the other 12 patients were defined as increased group.OS and PFS were compared betweem two groups.The prognostic factors were examined in the univariate and multivariate analysis,respectively.Results The median survival time,one-year survival rate and three-year survival rate of treatment group and untreatment group were 17.0 months,59.4%,31.5% and 18.7 months,56.4%,28.6%,respectively;There was no significant difference between treated group and untreated group.The median survival time,one-year survival rate and three-year survival rate of decreased group and increased group were 19.7 months,65.0%,42.1% and 10.7 months,43.3%,8.3%,respectivley;The decreased group had longer OS and PFS than increased group(x2 =4.345,4.157,P 〈 0.05).Multivariate analysis demonstrated that clinical staging was prognostic factor on OS,not sex and tumor location.Conclusions Thalidomide combined with radiotherapy is associated with longer OS and PFS in patients with esophageal carcinoma,especially for patients with VEGF decreasing.
出处 《中华放射医学与防护杂志》 CAS CSCD 北大核心 2015年第6期437-440,共4页 Chinese Journal of Radiological Medicine and Protection
基金 江苏省卫生厅指导性科研项目(Z201220) 常州市卫生局重大项目(ZD201105) 常州市科技支撑社会发展项目(CE20125021)
关键词 食管癌 放疗 血管内皮生长因子 沙利度胺 Esophageal cancer Radiotherapy Vascular endothelial growth factor Thalidomide
  • 相关文献

参考文献13

  • 1孙志强,倪新初,王坚,李毅,胡莉钧,李栋庆,孙苏平.沙利度胺联合放疗治疗食管癌的临床观察[J].中华放射医学与防护杂志,2012,32(4):369-373. 被引量:16
  • 2Sekis I, Gerner W, Willmann M,et al. Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell [J]. Am J Yet Res, 2009, 70(9):1141-1150.
  • 3于静萍,孙志强,倪新初,王坚,李毅,胡莉钧,李栋庆,孙苏平.食管癌患者放疗前后血清血管内皮生长因子变化的临床意义[J].中华放射医学与防护杂志,2011,31(6). 被引量:12
  • 4Nieman DR, Peters JH. Treatment strategies for esophageal cancer[J]. Gastroenterol Clin North Am, 2013, 42(1):187-197.
  • 5Peng J, Shao N, Peng H, et al. Prognostic significance of vascular endothelial growth factor expression in esophageal carcinoma: a meta-analysis[J]. BUON, 2013, 18(2):398-406.
  • 6Xu XL, Ling ZQ, Chen W, et al. The overexpression of VEGF in esophageal cancer is associated with a more advanced TMN stage: a meta-analysis[J]. Cancer Biomark, 2013, 13(2):105-113.
  • 7樊锐太,刘云,王鑫,孙银银,吴竞.恩度联合放化疗治疗中晚期食管癌的临床观察[J].中国实用医刊,2014,41(6):13-15. 被引量:7
  • 8Stewart AK. How thalidomide works against cancer[J]. Science, 2014, 43(6168):256-257.
  • 9Ohm JE, Gabrilovich DI, SemPowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression[J]. Blood, 2003, 101(12):4878-4886.
  • 10Bellati F, NaPoletano C, GasParri ML, et al. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms[J]. Crit Rev Oncol Hematol, 2012, 83(1):35-46.

二级参考文献33

  • 1于静萍,孙志强,倪新初,王坚,李毅,胡莉钧,李栋庆,孙苏平.食管癌患者放疗前后血清血管内皮生长因子变化的临床意义[J].中华放射医学与防护杂志,2011,31(6). 被引量:12
  • 2王修身,刘孟忠,张昌卿,蔡玲,崔念基.同期放化疗对食管癌患者血清血管内皮生长因子表达水平的影响——附43例临床资料分析[J].癌症,2006,25(11):1428-1432. 被引量:2
  • 3孙燕,石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2009.
  • 4Su-Ping Sun,Ye-Ning Jin,Hong-Peng Yang,Yi Wei,Zhao Dong.Serum transforming growth factor-β1 level reflects disease status in patients with esophageal carcinoma after radiotherapy[J].World Journal of Gastroenterology,2007,13(39):5267-5272. 被引量:9
  • 5Davis M, Lasheen W, Walsh D, et al. A phase II dose titration study of thalidomide for cancer-associated anorexia. J Pain Symptom Manage, 2012, 43(1):78-86.
  • 6Zhao KL, Ma JB, Liu G, et al. Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary?. Int J Radiat Oncol Biol Phys, 2010, 76(2):446-451.
  • 7Yoon MS, Nam TK, Lee JS, et al. VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma. J Korean Med Sci, 2011, 26(4):513-520.
  • 8Takala H, Saarnio J, Wiik H, et al. HIF-1alpha and VEGF are associated with disease progression in esophageal carcinoma. J Surg Res, 2011, 167(1):41-48.
  • 9Tzao C, Lee SC, Tung HJ, et al. Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis Markers, 2008, 25(3):141-148.
  • 10Sekis I, Gerner W, Willmann M, et al. Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell line. Am J Vet Res, 2009, 70(9):1141-1150.

共引文献29

同被引文献95

引证文献9

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部